Ukuphulukiswa Kwamayeza Kubonisa Isethembiso
Sibutsetelo
I-Naltrexone iyisidakamizwa esivumelwaneni esijwayelekile sama-50 kuya ku-100 mg, esivimbela imiphumela ye-opioids. Ezikhathini eziphansi kakhulu, abanye abacwaningi bakholelwa ukuthi lesi sidakamizwa singaba usizo kubantu abane fibromyalgia nesifo esingapheliyo sokukhathala ; izifo ezithintekayo / izifo ezivuthayo ezihlanganisa ukubola kwesifo , isifo esiyinkimbinkimbi yesifo sezwe, nesifo sikaCrohn; nezinye izifo ezihlobene negciwane , njenge- HIV / AIDS .
I-low-dose naltrexone (i-LDN) yisidakamizwa esingabizi esivele emakethe, okuye kwavuselela injabulo mayelana nokusetshenziswa kwayo okusemandleni. Ucwaningo luhamba kancane kancane, noma kunjalo, ngenxa yokuthi ayikho inzuzo enkulu yezezimali.
I-LDN isebenza kanjani?
Abacwaningi abasiqondi kahle indlela esetshenziswa ngayo izidakamizwa. Abanye abacwaningi bacabanga ukuthi i-LDN ivimbela ama-receptors athile ohlelweni lwezinzwa ezibangela izimpawu ze-fibromyalgia nesifo esingapheliyo sokukhathala.
Ubufakazi obunye bubonisa ukuthi i-LDN isebenza njenge-anti-inflammatory ohlelweni lwezinzwa zomphakathi nolunye, mhlawumbe ngokunciphisa umsebenzi wamaseli akhethekile okuthiwa i-microglia.
Ucwaningo lubonisa nokuthi i-LDN ingasiza ukuvuselela isimiso somzimba sokuzivikela, okungenzeka ukuthi kubonakala sengathi sisiza abantu abanokugula kanye nezinye izifo zesistimu ye-immune.
Funda kabanzi mayelana nokuvuvukala nokuzimela ngokuzenzakalelayo ku-fibromyalgia nesifo esingapheliyo sokukhathala:
Nge-Fibromyalgia
Uchungechunge lwezifundo zaseStanford University luye lwabonisa imiphumela emihle-okuningi njengokunciphisa amaphesenti angu-30 ezimpawu uma kuqhathaniswa ne-placebo. Abacwaningi bathi imiphumela ihamba phambili kubantu abanamazinga aphezulu, okukhombisa impendulo yokuvuvukala emzimbeni.
(Izinga eliphakeme eliphezulu lingabonisa isimo esidlulayo ngoba ngokuvamile asikhulumi ku-fibromyalgia.)
Imiphumela ibonisa nokuthi izidakamizwa zibekezeleleke kahle.
Kodwa-ke, lezi zifundo sonke sezibe zincane futhi umsebenzi omningi udinga ukwenziwa ngaphambi kokuba sazi ukuthi i-LDN ephephile futhi ephumelelayo yalesi simo.
I-LDN ayilona i-FDA evunyelwe i-fibromyalgia kodwa ngezinye izikhathi ibhalwe ngaphandle-ilebula.
For Chronic Chronic Fatigue Syndrome
Kuze kube manje, i-LDN ingakafundiwe nge-syndrome engapheliyo yokukhathala. Nokho, abanye odokotela neziguli bathi bayisebenzise ngempumelelo.
Njengoba ubufakazi bamuva bukhomba ukuthi kungenzeka ukuthi i- neuroinflammation e-chronic fatigue syndrome kanye nomthelela we-LDN onamandla ekuvuvukala ohlelweni lwezinzwa, singase sibone ukuthi kungani lokhu kungokwelashwa okuphumelelayo kwabanye.
Njengomuthi we-fibromyalgia, i-LDN ngezinye izikhathi ishiwo ngaphandle kwelebuli ye-syndrome engapheliyo.
Isilinganiso
Ukuze isetshenziswe ekuphatheni i-fibromyalgia noma isifo esingapheliyo sokukhathala, i-naltrexone ngokuvamile inikezwa ngama-4.5 mg noma ngaphansi. Ngokuvamile, uzoqala ku-1.5 mg, usebenze kuze kufike ku-3 mg, bese ukwandisa ube ngu-4.5.
Imiphumela ebangelwa umthamo ophansi awubonakali kumazinga aphezulu.
Okuqhamuka uma udla imishanguzo
Ngenkathi i-LDN ibonakala ibekezelela kahle, imiphumela emibi eyaziwayo ye-naltrexone ihlanganisa:
- isiyezi no-syncope (ukuphelelwa amandla)
- ikhanda
- ukulala
- ukukhathazeka nokukhathazeka
- ukulala nokukhathala
- ukunxanxathela, ukuhlanza, isifo sohudo, ubuhlungu besisu / ukugumbana, ukunciphisa ukudla
- injection site ubuhlungu & ukuvuvukala
- ubuhlungu obuhlangene
- ukuhlukumeza ngokwemisipha ngokweqile
- ukutheleleka okuphezulu kokuphefumula
- Umphimbo obuhlungu
Esifundweni saseStanford, imiphumela emibi yabikwa njengeyavamile, imnene, futhi iphelile.
Abantu abanesifo sezinso noma isibindi bangadinga ukuhlolwa okukhethekile noma imithi ukuze bathathe i-LDN ngokuphepha. Lesi sidakamizwa singase sibe yingozi kumntwana ongakazalwa. Asisazi ukuthi ngabe idlula ubisi lwebele.
I-LDN ne-opioid Painkillers
Ngama-dose amakhulu, i-naltrexone isetshenziselwa ukunciphisa ama-opiate (ama-narcotic) ama-painkillers afana ne- Vicodin (i-hydrocodone acetaminophen) ne- OxyContin (oxycodone) ngoba ivimbela ukusebenza kwabo ebuchosheni.
Kusebenza ekusebenziseni i-opiate kumazinga aphansi awaziwa okwamanje, kodwa kubhekwa njengombono omubi wokuhlanganisa lezi zidakamizwa. Qinisekisa ukuthi ukhuluma nodokotela wakho mayelana nokuthi kufanele uhambe isikhathi esingakanani ama-opioid ngaphambi kokuqala i-LDN.
Ingabe Kukulungele?
Uma unesithakazelo ekuvivinyeni i-LDN, khuluma nodokotela wakho mayelana nezinzuzo nezingozi. Nakuba odokotela abathile bebeka i-LDN kubantu abanezifo kanye nabanye abaningi, kusabhekwa njengokwelashwa okuphuthumayo, ngakho-ke udokotela wakho angase angafuni ukuyihlola.
Imithombo:
Ablin JN, Buskila D. Umbono wezobuchwepheshe ngezidakamizwa ezikhulayo. 2010 Sep; 15 (3): 521-33. Imithi yokwelapha ye-fibromyalgia: isibuyekezo.
I-Plesner KB, Vaegter HB, Handberg G. Ugeskrift we-laeger. 2015 Okthoba 9; 177 (43): V03150248. Isilinganiso esincane se-naltrexone sokwelashwa ubuhlungu. [Abstract abhekisiwe. Isihloko ngesiDanish.]
I-Younger J, iMackey S. Imithi yokwelapha. 2009 Meyi-Jun; 10 (4): 663-72. "Izimpawu Ze-Fibromyalgia Zinciphiswa Ngama-Naltrexone Ephansi-I-A Study Pilot."
I-Younger J, et al. I-arthritis ne-rheumatism. 2013 Feb; 65 (2): 529-38. I-do-low-dose naltrexone yokwelashwa kwe-fibromyalgia: ukutholakala kwecala elincane, elingenakulinganiswa, eliphindwe kabili, elingenalutho, elibhekene ne-placebo, elilinganiselwe, le-crossover elihlola amazinga obuhlungu nsuku zonke.
I-Younger J, uParkitny L, McLain D. I-rheumatology yezokwelapha. 2014, 33 (4): 451-9. Ukusetshenziswa kwe-do-low naltrexone (i-LDN) njenge-anti-inflammatory treatment for inferior pain.